CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK) . CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis In Vitro CC-90001 blocks LPS-induced c-jun phosphorylation with an EC 50 of 480 nM in cellular assays. CC-90001 is 12.9-fold more potent for JNK1 inhibition than JNK2 using JNK1 and JNK2 knockout fibroblasts. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo CC-90001 (3 mg/kg b.i.d.) reduces the development of fibrosis, as evidenced by a 48% reduction in collagen and a 53% reduction in α-smooth muscle actin (α-SMA) in a steatohepatitis model . CC-90001 decreases multiple measures of lung collagen and reduces disease induced increases in α-SMA to nearly baseline levels in a house dust mite model of lung fibrosis . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:JNK1 JNK2